Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -413.84M | -382.71M | -323.01M | -272.55M | -259.34M |
| Total Depreciation and Amortization | 377.00K | 332.00K | 291.00K | 258.00K | 231.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.62M | 47.84M | 46.68M | 44.79M | 42.25M |
| Change in Net Operating Assets | -12.03M | 9.60M | 4.39M | -15.55M | 2.63M |
| Cash from Operations | -375.87M | -324.94M | -271.64M | -243.06M | -214.23M |
| Capital Expenditure | -759.00K | -708.00K | -659.00K | -497.00K | -360.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -759.00K | -708.00K | -659.00K | -497.00K | -360.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 454.81M | 5.43M | 478.82M | 478.24M | 478.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -319.00K | 0.00 | -6.01M | -6.01M | -6.01M |
| Cash from Financing | 454.49M | 5.43M | 472.81M | 472.22M | 472.43M |
| Foreign Exchange rate Adjustments | 747.00K | 3.97M | 2.51M | 1.38M | 993.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 78.61M | -316.25M | 203.01M | 230.05M | 258.83M |